Centre for Commercialization of Regenerative Medicine-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Centre for Commercialization of Regenerative Medicine - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014247
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Centre for Commercialization of Regenerative Medicine (CCRM) is an healthcare service provider that offers cell reprogramming and engineering, cell manufacturing, bio materials and devices manufacturing. The center’s cell reprogramming and engineering offers various capabilities such as establishment of cell lines, cell banking of public, private, or specialty collections, mycoplasma testing, remote fail-safe storage and reagents and protocols. It also provides repair, regenerate or replace diseased cells, tissues and organs. The center collaborates with multinationals, small-medium enterprises and biotechnology companies, among others. CCRM is headquartered in Toronto, Ontario, Canada.

Centre for Commercialization of Regenerative Medicine – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Centre for Commercialization of Regenerative Medicine and Affigen Enter into Partnership 10
Hemostemix Enters into Co-Development Agreement with Commercialization of Regenerative Medicine 11
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 12
Centre for Commercialization of Regenerative Medicine – Key Competitors 13
Centre for Commercialization of Regenerative Medicine – Key Employees 14
Centre for Commercialization of Regenerative Medicine – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Other Significant Developments 16
Jan 13, 2016: GE Healthcare, FedDev Ontario commit CAD $40M for new CCRM-led centre to solve cell therapy manufacturing challenges 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Key Facts 2
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Centre for Commercialization of Regenerative Medicine, Deals By Therapy Area, 2011 to YTD 2017 8
Centre for Commercialization of Regenerative Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Centre for Commercialization of Regenerative Medicine and Affigen Enter into Partnership 10
Hemostemix Enters into Co-Development Agreement with Commercialization of Regenerative Medicine 11
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 12
Centre for Commercialization of Regenerative Medicine, Key Competitors 13
Centre for Commercialization of Regenerative Medicine, Key Employees 14

★海外企業調査レポート[Centre for Commercialization of Regenerative Medicine-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank of England:企業の戦略・SWOT・財務情報
    Bank of England - Strategy, SWOT and Corporate Finance Report Summary Bank of England - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Trustpower Limited:企業の戦略的SWOT分析
    Trustpower Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • ICL Group Ltd (ICL):企業の財務・戦略的SWOT分析
    ICL Group Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析
    Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Seair, Inc. (SDS)-石油・ガス分野:企業M&A・提携分析
    Summary Seair, Inc. (Seair) is a clean technology company that carries out research and development, production and sale of diffusion and sterilization technologies. It focuses on commercializing advanced waste water and industrial fluid treatment solutions. The company offers high performance propr …
  • AutoZone, Inc.:戦略・SWOT・企業財務分析
    AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report Summary AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Electra Private Equity PLC (ELTA):企業の財務・戦略的SWOT分析
    Electra Private Equity PLC (ELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Pakistan Water and Power Development Authority:企業の戦略的SWOT分析
    Pakistan Water and Power Development Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Tabuk Pharmaceuticals Manufacturing Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Tabuk Pharmaceuticals Manufacturing Company (Tabuk), a subsidiary of Astra Industrial Group, is a drug company that develops, manufactures and markets branded generic pharmaceuticals and under-licensed products. The company offers products in various therapeutic areas including alimentary tr …
  • Australian Mines Limited:企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Clementia Pharmaceuticals Inc (CMTA)-製薬・医療分野:企業M&A・提携分析
    Summary Clementia Pharmaceuticals Inc (Clementia) is a biopharmaceutical company that develops and commercializes orphan drugs and therapies. The company’s palovarotene is used for treatment of muscle tissue disorders such as fibrodysplasia ossificans progressive and other diseases. Its palovarotene …
  • Pt Bakrieland Development Tbk:企業の戦略・SWOT・財務分析
    Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • The Nisshin OilliO Group, Ltd.:企業の戦略・SWOT・財務分析
    The Nisshin OilliO Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Nisshin OilliO Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Fusion Telecommunications International, Inc.:企業のM&A・事業提携・投資動向
    Fusion Telecommunications International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fusion Telecommunications International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • Global Clean Energy Holdings Inc (GCEH):企業の戦略的SWOT分析
    Global Clean Energy Holdings Inc (GCEH) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Universal Health Services, Inc.:企業の戦略・SWOT・財務情報
    Universal Health Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Universal Health Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Apogenix AG-製薬・医療分野:企業M&A・提携分析
    Summary Apogenix AG (Apogenix) is a biopharmaceutical company, developing immuno-oncology medicines for the treatment of cancer and other malignant diseases. Its pipeline drug candidates under clinical development include Asunercept (APG101), a CD95 ligand inhibitor, for the treatment of glioblastom …
  • Ergomed Plc (ERGO):製薬・医療:M&Aディール及び事業提携情報
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd is a drug development and clinical research services provider. The company provides service portfolio such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • PT Bank Central Asia Tbk:企業の戦略・SWOT・財務情報
    PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆